文献速递肿瘤 PET/CT

镓-68标记生长抑素受体拮抗剂PET/CT在逾500例神经内分泌肿瘤患者中的应用:中国单中心经验

Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-02-10

该研究回顾性分析了北京协和医院自2018年11月以来549例确诊或疑似神经内分泌肿瘤患者的622次生长抑素受体拮抗剂PET/CT扫描,患者水平灵敏度、特异度和准确度分别为91.0%、91.9%和91.1%。在181例有配对的镓-68 DOTATATE PET/CT患者中,拮抗剂显像的灵敏度、特异度和准确度分别为87.5%、76.9%和86.7%,所有拮抗剂的肿瘤-肝脏比值均显著高于镓-68 DOTATATE。

要点

  • 生长抑素受体拮抗剂PET/CT在神经内分泌肿瘤患者中患者水平灵敏度91.0%、特异度91.9%、准确度91.1%。
  • 所有拮抗剂肿瘤-肝脏比值显著高于镓-68 DOTATATE(12.1±10.8 vs 5.2±4.5,p<0.001)。
  • 镓-68 NODAGA-LM3的SUVmax显著高于镓-68 DOTATATE(57.4±38.5 vs 40.0±22.8,p<0.001)。

核心结论

  • 镓-68标记生长抑素受体拮抗剂可作为生长抑素受体激动剂的替代方案用于神经内分泌肿瘤显像,其中镓-68 NODAGA-LM3似乎具有最佳显像特征。

研究设计与样本

  • 回顾性分析北京协和医院自2018年11月以来确诊或疑似神经内分泌肿瘤患者的生长抑素受体拮抗剂PET/CT扫描,共纳入549例患者的622次扫描。
  • 使用了四种生长抑素受体拮抗剂:[68Ga]Ga-NODAGA-LM3、[68Ga]Ga-DOTA-LM3、[68Ga]Ga-NODAGA-JR11和[68Ga]Ga-DOTA-JR11。
  • 参考标准基于组织病理学、临床评估、影像结果和随访的组合。

主要发现

  • 拮抗剂显像(所有示踪剂合并)患者水平灵敏度91.0%(443/487)、特异度91.9%(57/62)、准确度91.1%(500/549)。
  • 在181例有配对[68Ga]Ga-DOTATATE PET/CT的患者中,患者水平灵敏度87.5%(147/168)、特异度76.9%(10/13)、准确度86.7%(157/181)。
  • 所有拮抗剂合并的最热病灶SUVmax与[68Ga]Ga-DOTATATE总体相当(40.1±32.5 vs 39.4±23.8,p=0.772)。
  • [68Ga]Ga-NODAGA-LM3的SUVmax显著高于[68Ga]Ga-DOTATATE(57.4±38.5 vs 40.0±22.8,p<0.001)。
  • [68Ga]Ga-NODAGA-JR11(39.7±26.5 vs 34.3±23.9,p=0.108)和[68Ga]Ga-DOTA-LM3(38.9±32.1 vs 37.2±22.1,p=0.858)的SUVmax与[68Ga]Ga-DOTATATE相当,[68Ga]Ga-DOTA-JR11的SUVmax低于[68Ga]Ga-DOTATATE(28.9±26.1 vs 44.0±25.7,p=0.001)。

关键数值与推荐

  • 患者水平灵敏度、特异度和准确度基于组织病理学、临床评估、影像结果和随访的组合参考标准计算。
  • 记录了最热病灶的SUVmax和肿瘤-肝脏比值,并在拮抗剂与[68Ga]Ga-DOTATATE之间进行比较。

临床怎么用

  • 作者认为镓-68标记生长抑素受体拮抗剂可作为生长抑素受体激动剂的替代方案用于神经内分泌肿瘤显像。
  • 作者认为在各种拮抗剂中,[68Ga]Ga-NODAGA-LM3似乎具有最佳显像特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Somatostatin receptor antagonists have shown promising performance for imaging neuroendocrine neoplasms. However, there is a lack of studies exploring the diagnostic performance of SSTR antagonists or comparing them with agonists in a large cohort of patients with NENs. This study aimed to retrospectively review all SSTR antagonist PET/CT scans conducted at Peking Union Medical College Hospital since November 2018 in patients with confirmed or suspected NENs. METHODS: Four types of SSTR antagonists were utilized, including [68Ga]Ga-NODAGA-LM3, [68Ga]Ga-DOTA-LM3, [68Ga]Ga-NODAGA-JR11, and [68Ga]Ga-DOTA-JR11. The reference standard was based on a combination of histopathology, clinical evaluation, imaging results, and follow-up. Patient-based sensitivity, specificity, and accuracy were evaluated. The SUVmax and tumor-to-liver ratio (TLR) of the hottest lesions was recorded and compared between antagonists and [68Ga]Ga-DOTATATE. RESULTS: A total of 622 antagonist scans from 549 patients were included in the analysis. The patient-level sensitivity, specificity, and accuracy of antagonist imaging (all tracers combined) were 91.0% (443/487), 91.9% (57/62), and 91.1% (500/549), respectively. In 181 patients with a comparative [68Ga]Ga-DOTATATE PET/CT scan, the patient-level sensitivity, specificity, and accuracy were 87.5% (147/168), 76.9% (10/13), and 86.7% (157/181), respectively. For the hottest lesions, SSTR antagonists all tracers combined demonstrated an overall comparable SUVmax to [68Ga]Ga-DOTATATE (40.1 ± 32.5 vs. 39.4 ± 23.8, p = 0.772). While [68Ga]Ga-NODAGA-LM3 showed significantly higher uptake than [68Ga]Ga-DOTATATE (57.4 ± 38.5 vs. 40.0 ± 22.8, p<0.001), [68Ga]Ga-NODAGA-JR11 (39.7 ± 26.5 vs. 34.3 ± 23.9, p = 0.108) and [68Ga]Ga-DOTA-LM3 (38.9 ± 32.1 vs. 37.2 ± 22.1, p = 0.858) showed comparable uptake to [68Ga]Ga-DOTATATE, and [68Ga]Ga-DOTA-JR11 showed lower uptake (28.9 ± 26.1 vs. 44.0 ± 25.7, p = 0.001). All antagonists exhibited significantly higher TLR than [68Ga]Ga-DOTATATE (12.1 ± 10.8 vs. 5.2 ± 4.5, p<0.001). CONCLUSION: Gallium-68 labeled SSTR antagonists could serve as alternatives to SSTR agonists for imaging of NENs. Among various antagonists, [68Ga]Ga-NODAGA-LM3 seems to have the best imaging profile.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu M, Cheng Y, Bai C, et al. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China. Eur J Nucl Med Mol Imaging. 2024. PMID: 38337073. doi:10.1007/s00259-024-06639-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。